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Background: Breast cancer incidence in women increases with age, while survival rates decrease. Studies interpret
this result as meaning higher comorbidity, diagnosis at later stages of the disease, and less effective treatment in
the elderly. The aim of this study is to evaluate the diagnosis and treatment characteristics of breast cancer and
their effect on the survival of women aged 65 and above.
Methods: The data within the files of 1064 women with breast cancer, who were followed-up in Dokuz Eylul
University Medical Faculty Hospital between 2000 and 2006, were reviewed retrospectively. The survival probabilities
at years 1 and 5 were calculated by life table analysis. The Kaplan-Meier test was used for calculating mean survival
time, and the differences between groups were evaluated by log-rank test. The backward elimination method was
used for multivariate analysis, and a −2 log-likelihood ratio was used for comparison of different models.
Results: Of the patients, 25.3% were aged 65 and above at the time of the diagnosis. Patients in this group had
more comorbidities and were more likely to be diagnosed at advanced stages than younger patients. Additionally,
they had lower rates of surgical treatment, chemotherapy or radiotherapy. One and 5-year survival probabilities
among age groups were 96.1% and 84.5%, respectively, for <65 years, 93.5% and 84.8%, respectively, for 65–69,
98.7% and 84.0%, respectively, for 70–74, and 85.5% and 59.6%, respectively, for 75 years and above. In the
multivariate model, age, clinical stage, and comorbidity were found to be negatively associated with the
survival rate.
Conclusions: The survival of women with breast cancer aged 65 and above was affected negatively by age at
diagnosis, clinical stage, and the presence of comorbidity. Early diagnosis also is very important for elderly women.
Additionally, because of higher comorbidity, their evaluation and treatment should be planned by an
interdisciplinary team.
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It is known that breast cancer incidence is rather low
before the age of 30 (25 in 100,000) and demonstrates a
linear increase through the age of 80, where it reaches a
plateau (around 500 in 100,000). Age is the most im-
portant risk factor in breast cancer occurrence after
gender. It is observed that the relative risk for breast
cancer increases by 5.8 times in women aged 65 and* Correspondence: mehtapkartal@gmail.com
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reproduction in any medium, provided the orabove compared with women below age 65 [1]. Projec-
tions by the United Nations have shown that breast
cancer incidence is increasing rather rapidly among
women aged 50 and above [2]. In Turkey, the preva-
lence of breast cancer based on records of women var-
ies between 21.4 and 45.6 per 100,000, placing this
disease at the top in terms of frequency of occurrence
[3]. It was seen that among 11,208 women with breast
cancer registered to 13 breast centers in eight prov-
inces, 40.7% were between 51 and 70 years of age and
8.2% were aged 70 and above [4].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Descriptive characteristics of women with breast
cancer
n %











Comorbidity (n=690) No 557 80.7
Yes 133 19.3




Histology (n=1012) Invasive ductal ca 473 46.7
Invasive lobular ca 220 21.7
Mixed 182 18.0
Others 137 13.5
Histologic grade (n=745) 1 119 16.0
2 338 45.3
3 288 38.7
Lymphovascular invasion (n=849) No 174 20.5
Yes 675 79.5
Surgery (n=1010) No 52 5.1
Yes 958 94.9
Chemotherapy (n=824) No 187 22.7
Yes 637 77.3
Radiotherapy (n=794) No 28 3.5
Yes 766 96.5
Hormonotherapy (n=703) No 113 16.1
Yes 590 83.9
Recurrence (n=545) No 490 89.9
Yes 55 10.1
Metastases (n=608) No 415 68.3
Yes 193 31.7
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cer diagnosed at later ages is worse than that of younger
women. In relation to this, cardiovascular diseases, pre-
existing cancer, diabetes mellitus and dementia are
mentioned among those diseases that most frequently ac-
company breast cancer in the elderly. It has also been
pointed out that these diseases increase the risk of death
[5-7]. The reasons why survival is lower in the elderly
while breast cancer in this age group displays less aggres-
sive tumor characteristics compared with the young have
been examined. Among the reported reasons are that the
diagnosis occurs in later stages and that the elderly receive
less surgical treatment, are insufficiently treated, and re-
ceive less radiotherapy following breast-conserving surgery
and chemotherapy [7-11]. The fact that patients from
older age groups do not participate in many randomized
controlled studies that assess the effectiveness of chemo-
therapies has meant that the most appropriate treatment
for the elderly is still being discussed [12].
When the survival probabilities of women were assessed
by age, it was seen that all of the women aged 65 years
and above who were diagnosed in stage 0 and 1 were alive
at the end of 5 years, while their survival was between
83.9% and 87.8% in stage 2, 41.5% and 57.8% in stage 3,
and 14.8% and 20.3% in stage 4 [13]. Among the factors
that influence the survival of patients with breast cancer,
histological grade and the presence of lymphovascular in-
vasion (LVI), particularly for those with negative lymph
node, are significant apart from clinical staging [14-17].
In light of previous studies, the aim of this study was
to determine certain diagnostic and treatment character-
istics of women with breast cancer aged 65 and above,
and compare their overall survival time, survival prob-
abilities, and factors that might influence their survival
with women younger than 65 years of age.
Methods
The study included 1064 female patients who were
followed up with a breast cancer diagnosis and/or
treatment in Dokuz Eylul University Medical Faculty
Hospital between January 1st, 2000 and December 31st,
2006. The data on the patients were obtained by exam-
ining the patient files, hospital information systems and
pathological reports retrospectively. The study was com-
pleted after the final monitoring status of the patients
determined on December 31st, 2011. Approval was ob-
tained from Dokuz Eylul University Medical Faculty
Hospital Ethics Committee.
Cox proportional hazards models were used to evaluate
the associations of age, comorbidity, clinical stage, histo-
logical grade, lymphovascular invasion, recurrence and
metastasis in the follow-up period with mortality. Survival
status was censored at the date of last in-person contact
noted patient files, hospital information systems orDecember 31st, 2011. The duration from diagnosis to
death was accepted as overall survival time. The ages of the
patients were given as <65, 65–69, 70–74, ≥75 years. Dis-
eases included in comorbid conditions were cardiovascular
diseases, pre-existing cancer, diabetes mellitus as they are
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in the elderly.
Statistical analysis
Categorical variables were presented with frequency
and percentage distributions, while continuous variables
were given with mean and standard deviation values.
The 5-year survival probabilities were calculated by life
table analysis. The mean survival times were calculated
with the Kaplan-Meier test, and the differences between
groups were evaluated by the log-rank test. The prognosticTable 2 Some characteristics of women with breast cancer ac
<65 65-6
Comorbidity (n=686)
No 437 (88.1) 49 (65
Yes 59 (11.9) 26 (34
Stage (n=906)
1 167 (24.3) 15 (17
2 313 (45.5) 42 (47
3 154 (22.4) 18 (20
4 54 (7.8) 13 (14
Histologic grade (n=740)
1 84 (14.9) 11 (16
2 249 (44.1) 35 (52
3 231 (41.0) 21 (31
Lenfovascular invasion (n=845)
No 133 (20.5) 21 (28
Yes 515 (79.5) 54 (72
Surgery (n=1002)
No 20 (2.6) 9 (9.6
Yes 737 (97.4) 85 (90
Chemotherapy (n=818)
No 112 (17.5) 18 (24
Yes 527 (82.5) 57 (76
Radiotherapy (n=791)
No 15 (2.4) 4 (5.6
Yes 601 (97.6) 68 (94
Hormonal therapy (n=697)
No 96 (18.0) 8 (13
Yes 438 (82.0) 53 (86
Recurrence (n=543)
No 380 (90.9) 44 (84
Yes 38 (9.1) 8 (15
Metastasis (n=604)
No 324 (69.7) 38 (66
Yes 141 (30.3) 19 (33values of all related variables were first assessed in univari-
ate analyses. Then the variables that had significant associ-
ation with the outcome were included in a multivariate
Cox proportional hazard model using the backward elim-
ination method, with −2 log-likelihood ratio values taken
into consideration for comparison of different models.
The proportional hazards assumption was checked with a
log minus log plot for each variable in the model.
The data were analyzed with the SPSS 15.0 program.
All reported p values are two-tailed and p<0.05 was ac-
cepted as statistically significant.cording to their age at the time of diagnosis
Age groups n (%) p-value
9 70-74 ≥75
<0.001
.3) 40 (60.6) 28 (57.1)
.7) 26 (39.4) 21 (42.9)
0.068
.0) 17 (21.8) 9 (17.3)
.7) 35 (44.9) 24 (46.2)
.5) 14 (17.9) 9 (17.3)
.8) 12 (15.4) 10 (19.2)
0.034
.4) 12 (18.2) 12 (27.9)
.3) 29 (43.9) 24 (55.8)
.3) 25 (37.9) 7 (16.3)
0.161
.0) 9 (12.9) 10 (19.2)
.0) 61 (87.1) 42 (80.8)
<0.001
) 9 (10.3) 11 (17.2)
.4) 78 (89.7) 53 (82.8)
<0.001
.0) 30 (48.4) 27 (64.3)
.0) 32 (51.6) 15 (35.7)
0.010
) 5 (8.3) 4 (9.3)
.4) 55 (91.7) 39 (90.7)
0.110
.1) 6 (10.5) 3 (6.7)
.9) 51 (89.5) 42 (93.3)
0.246
.6) 38 (86.4) 28 (96.6)
.4) 6 (13.6) 1 (3.4)
0.755
.7) 30 (62.5) 23 (67.6)
.3) 18 (37.5) 11 (32.4)
Table 3 Survival rates of women with breast cancer
according to their age and stage at the time of diagnosis
Stages Age groups
<65 65-69 70-74 ≥75
1 98.0 91.7 94.1 75.2
5 year survival*
2 91.4 92.5 89.8 77.4
3 72.5 81.0 72.5 37.5
4 23.4 40.2 43.2 33.8
*Life table analysis.
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The mean follow up period was 74.6±39.8 months with
a median of 77 months. Certain characteristics of the
women included in the study are given in Table 1. Ages





65-69 0.6 0.2 1.5
70-74 1.2 0.5 2.5
≥75 3.6 1.2 11.0
Comorbidity
No*
Yes 2.3 1.3 4.1
Stage
1*
2 2.0 0.8 5.0
3 6.4 2.4 16.7
4 21.5 6.5 70.6
Histologic grade
1*
2 1.8 0.8 4.2
3 2.5 1.1 5.8
Surgical treatment
Yes*
No 1.1 0.3 3.3
Chemotherapy
Yes*
No 1.2 0.5 3.1
Radiotherapy
Yes*
No 1.2 0.3 3.9
−2 log likelihood ratio 788.363
*Indicates reference category.
HR Hazard ratio (ß).
CI Confidence interval.24 and 90 years, and 25.3% were aged ≥65 years. The
mean age of this subgroup was 71.9±5.4 years at the
time of the diagnosis.
The distribution of some characteristics of the patients
in terms of age is summarized in Table 2. Women aged
>65 years had more comorbid diseases than younger
women (p<0.001). The clinical stages in which the women
were diagnosed in terms of their ages were found not to
be significantly different (p=0.068), with 19.2% of those
≥75 years at clinical stage 4 at diagnosis. Patients aged <65
years received more surgical treatment (97.4%), chemo-
therapy (82.5%) and radiotherapy (97.6%) than those who
were older.
The mean survival times for the age groups were 121.0
months for the <65 years of age group, 119.0 months for
the 65–69 years of age group, 121.4 months for the 70–survival of women with breast cancer
Reduced model
p HR %95 CI p
0.047 0.025
0.252 0.5 0.2 1.4 0.189
0.710 1.1 0.5 2.4 0.773
0.023 3.0 1.3 6.8 0.009
0.003 2.3 1.4 4.0 0.002
<0.001 <0.001
0.149 2.1 0.9 4.9 0.072
<0.001 7.1 3.0 16.4 <0.001
<0.001 22.5 8.7 58.4 <0.001
0.085 0.075
0.152 1.8 0.8 4.2 0.149
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of age group (median survival time=86.0 months) (Log
rank chi-square=16.288; p<0.001). The 5-year survival
probabilities of patients in terms of age group were
84.5% for age <65 years, 84.8% for age 65–69 years,
84.0% for age 70–74 years, and 59.6% for age ≥75 years.
The survival probabilities by age group and clinical stage
are given in Table 3.
In addition to age and clinical stage, the final model
included co-morbid disease, histological grade, surgical
treatment, chemotherapy and radiotherapy. These add-
itional factors are shown to influence survival and be
significantly different among groups. When all these vari-
ables were corrected in relation to one another but no var-
iables were eliminated, age, clinical stage and comorbidity
was found to be statistically significant (p<0.05). The re-
duced model included age, clinical stage, comorbidity and
histologic grade (Table 4). In the ≥75 years of age group,
increasing clinical stage and histologic grade, presence of
comorbidity increased the hazard ratios (HR) of the pa-
tients. Presence of comorbidity increased the HR 2.3 times
independently of the age at diagnosis, clinical stage and
histological grade of the disease. When the survival curves
of the reduced model are evaluated, the survival probabil-
ities of the patients aged <65 years were found to be simi-
lar to 70–75 years of age group while 65–69 years of age
group was better than both of them. And women over 75
years of age distinctly differ from younger women in all
age groups which may be interpreted as age of 75 may be
a breaking point for survival (Figure 1).Figure 1 Survival curves of women with breast cancer according to thDiscussion
The number of women with breast cancer increases with
increase in life span and increase in elderly population,
which in turn results in a higher increase in the number
of elderly women with cancer. Breast cancer particularly
affects elderly women in developed countries [9]. A
multicentre study including 11,208 breast cancer pa-
tients from June 2005 until February 2008 showed that
8.2% were aged above 70 years, while in this study, pa-
tients aged above 65 years constituted 25.0% of all the
patients [4]. The mean age of our patients above 65
years was 71.9 years, while another single-centered study
including breast cancer patients aged above 65 years
found the mean age of an equivalent group to be 72.7
years [18].
Co-morbid diseases accompanying breast cancer occur
more frequently in elderly patients. It is known that in
the elderly without any comorbid diseases, the disease
displays a relatively good prognosis, whereas in those
with comorbid diseases, it has rather a poor one. It was
found in one study that comorbid disease increases the
hazard ratio by 1.3 times independent of age, stage and
treatment [6,8]. In our study, 34.2-44.4% of women aged
≥65 years have at least one disease accompanying breast
cancer, while only 11.9% of those aged ≤65 years have at
least one co-morbid disease. In the multivariate analysis,
co-morbid disease was found to increase the hazard ra-
tio by 2.3 times.
Impairments in organ functions, which occur as a re-
sult of increased age as well as co-morbid diseases in theeir age at the time of diagnosis.
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plan so that optimum treatment can be achieved. As a
consequence, elderly patients cannot be treated in an ag-
gressive way though they are diagnosed at later stages than
younger patients [9,19,20]. When assessed from the view-
point of surgical treatment, it has been reported that a
more limited surgical treatment is administered in the eld-
erly and that this situation is much more apparent in
patients aged ≥80 years [6]. It has been shown that breast-
conserving surgery is performed less often and that this
situation continues even after recovery from the co-morbid
disease is achieved [6-8]. The situation is similar with
radiotherapy and chemotherapy. While in various studies
patients aged ≥70 and ≥80 years are emphasized, the con-
sensus is that the patients in this age group receive less
chemotherapy and radiotherapy but more hormonal
therapy [6,7,19,20].
Even though it is known that patients are diagnosed
later with more advanced age, it has been shown that
this situation is also true for patients over 70. While pa-
tients diagnosed at stage 4 constitute 3.7% of people
aged <65 years, they constitute 8.5% of the age group
80–84 [20,21]. Similarly, we have also found in our study
that women aged ≥75 years could not benefit from im-
proved staging methods and therapies. They were diag-
nosed at later stages which can be due to the gab in the
screening programs or the ignorance of the disease and
rejection of its hard treatment process by the elderly as
these can easily affect their quality of life. They received
less surgical treatment, chemotherapy and radiotherapy
compared with patients in other age groups. This result
might indicate that clinicians are caught between the
short-term damage of special interventions in breast can-
cer and the death of patients due to other factors. More-
over, some studies indicate that breast cancer progresses
less aggressively in the elderly and thus the usual treat-
ment approaches are not required. However, the know-
ledge on this issue is limited and further research is
needed [9,18].
In the EUROCARE-3 study, the survival probabilities of
women at 5 years were 76% for ages 65–74 years and 69%
for ages above 75 years [22]. In SEER records, on the other
hand, survival at 5 years was 89.2% for women aged ≤65
years, 90.4% for ages 65–74 and 86.8% for ages above 75
years [23]. In a study conducted in Turkey, survival at 5
years for women aged ≥65 years was 62%. In the same
study, stage and lymph node involvement were reported to
be the most important factors affecting survival [18]. In
our study, it was observed that survival probabilities at 5
years decrease with increased age, to 59.6% for ages above
75 years. When age and clinical stage, which affect the sur-
vival rate of patients with breast cancer, were evaluated to-
gether, the age of 75 appears to be a breaking point with
markedly decreased survival rate.In studies that assess the effect of the increasing inad-
equacies and deficiencies in treatment due to age on pa-
tient survival, different results were obtained; nevertheless,
it has been shown that radiotherapy increased the overall
and disease-free survival while this influence could not be
confirmed for surgical treatment, radiotherapy and chemo-
therapy [7,10]. In the modeling made for this study, it can
also be seen that the presence of co-morbid disease in
addition to age and clinical stage influenced total survival
significantly, whereas surgical treatment, radiotherapy and
chemotherapy did not have any significant influence on
overall survival.
The most important limitation of our study is that the
data were collected retrospectively from existing patient
files, which brings the limitations of recorded patient in-
formation, including certain shortcomings and possible
mistakes.
Conclusions
In summary, women aged ≥65 years were diagnosed with
later stages of breast cancer. The co-morbid diseases of
these patients might limit physician choices of treatment.
Increased age, clinical stage and co-morbid diseases had a
negative impact on survival. The early diagnosis of breast
cancer is as important for the elderly as for the young and
it will be essential to re-evaluate the upper age limit de-
fined in national breast cancer screening programs. Fur-
thermore, planning the post-diagnosis assessment and
treatment of the functional losses and co-morbid diseases
occurring with aging with an interdisciplinary team are
important for the survival of patients.
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